Roche’s wildly successful Ocrevus (ocrelizumab) blockbuster, the breakthrough therapy for treatment of primary progressive multiple sclerosis, as well as relapsing MS, has emerged as a target for biosimilar developer Celltrion.
Meanwhile, Celltrion has filed its CT-P39 biosimilar Xolair (omalizumab) candidate with the European Medicines Agency, following recent publication of 24-week Phase III clinical comparative data
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?